Novel Pyrrolopyridazine VEGFR Tyrosine Kinase Inhibitors for Treating Cancer

ACS Medicinal Chemistry Letters 2026 Open access

Read full text
Authors: Ram W. Sabnis
DOI: 10.1021/acsmedchemlett.6c00108
Cited by: 1
References: 3

Abstract

High Resolution Image Download MS PowerPoint Slide Provided herein are novel pyrrolopyridazine VEGFR tyrosine kinase inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

Fields of Study & Subjects

Chronic Lymphocytic Leukemia Research HER2/EGFR in Cancer Research Chemotherapy-induced cardiotoxicity and mitigation

Publication details

Journal / source
ACS Medicinal Chemistry Letters
Publisher
American Chemical Society (ACS)
Volume
17
Issue
3
Pages
640–641
Publication date
3 March 2026
Language
EN